NCT05628974 Normal Donor Blood Draws for Platelet Studies and Biomarker Evaluation (ND-PLT)
| NCT ID | NCT05628974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Healthy |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2020-05-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2020-05-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center study at the Cleveland Clinic Main Campus designed to study biomarkers in healthy individuals to identify novel mechanisms of platelet activation and how platelets drive vascular inflammation and thrombosis in diseases.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years old * Healthy Male \& Female voluntary participants Exclusion Criteria: * Individuals who have taken anticoagulant or antiplatelet medications in past 10 days * Individuals with hematopoetic diseases
Contact & Investigator
Scott Cameron, MD, PhD
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT05628974 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05628974 currently recruiting?
Yes, NCT05628974 is actively recruiting participants. Contact the research team at cameros3@ccf.org for enrollment information.
Where is the NCT05628974 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT05628974 clinical trial?
NCT05628974 is sponsored by The Cleveland Clinic. The principal investigator is Scott Cameron, MD, PhD at The Cleveland Clinic. The trial plans to enroll 400 participants.